We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+30.69%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.46B
AUM Growth
+$453M
Cap. Flow
-$312M
Cap. Flow %
-5.72%
Top 10 Hldgs %
38.94%
Holding
132
New
22
Increased
22
Reduced
29
Closed
18

Top Buys

Rank Stock Value
1
AVBP icon
ArriVent BioPharma
AVBP
+$61.1M
2
CYTK icon
Cytokinetics
CYTK
+$52.8M
3
ESPR
Esperion Therapeutics
ESPR
+$33.3M
4
MRK icon
Merck
MRK
+$32.2M
5
QTTB icon
Q32 Bio
QTTB
+$31M

Top Sells

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$147M
2
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$93.5M
3
UTHR icon
United Therapeutics
UTHR
+$84.9M
4
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
+$71.7M
5
SWTX
SpringWorks Therapeutics
SWTX
+$69.9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.1%
2 Miscellaneous 0.9%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SVA
1
DELISTED
Sinovac Biotech, Ltd
SVA
$340M 6.23%
2,718,735
– –
LLY icon
2
Eli Lilly
LLY
$1.05T
$281M 5.14%
360,800
-4,600
-1% -$3.27M
EWTX icon
3
Edgewise Therapeutics
EWTX
$4.64B
$274M 5.02%
15,021,721
+454,545
+3% +$7.22M
BSX icon
4
Boston Scientific
BSX
$67.9B
$224M 4.11%
3,273,000
-33,800
-1% -$2.17M
ISRG icon
5
Intuitive Surgical
ISRG
$132B
$197M 3.6%
493,100
-5,900
-1% -$2.23M
BIIB icon
6
Biogen
BIIB
$32.3B
$194M 3.56%
900,900
+73,300
+9% +$17.2M
MRK icon
7
Merck
MRK
$366B
$174M 3.18%
1,316,000
+261,000
+25% +$32.2M
JANX icon
8
Janux Therapeutics
JANX
$1.1B
$161M 2.95%
4,275,553
+957,626
+29% +$20.9M
ELVN icon
9
Enliven Therapeutics
ELVN
$4.24B
$158M 2.9%
8,998,338
– –
THC icon
10
Tenet Healthcare
THC
$21.5B
$123M 2.26%
1,173,300
-51,100
-4% -$4.59M
BMRN icon
11
BioMarin Pharmaceuticals
BMRN
$12.5B
$112M 2.05%
1,278,500
-292,910
-19% -$26.2M
ALPN
12
DELISTED
Alpine Immune Sciences Inc
ALPN
$106M 1.95%
2,680,496
+145,251
+6% +$4.29M
IRON icon
13
Disc Medicine
IRON
$3.07B
$106M 1.94%
1,702,237
– –
SYK icon
14
Stryker
SYK
$127B
$96.3M 1.76%
269,000
– –
SPRY icon
15
ARS Pharmaceuticals
SPRY
$586M
$94.4M 1.73%
9,240,887
– –
SRPT icon
16
Sarepta Therapeutics
SRPT
$2.2B
$90.3M 1.65%
697,500
– –
IONS icon
17
Ionis Pharmaceuticals
IONS
$10.1B
$87.3M 1.6%
2,013,033
-51,764
-3% -$2.47M
ELV icon
18
Elevance Health
ELV
$85.5B
$87.2M 1.6%
168,100
+26,600
+19% +$13.2M
XTNT icon
19
Xtant Medical Holdings
XTNT
$53.9M
$85.5M 1.57%
73,114,592
– –
EVH icon
20
Evolent Health
EVH
$520M
$85.4M 1.56%
2,605,615
-140,917
-5% -$4.5M
SWTX
21
DELISTED
SpringWorks Therapeutics
SWTX
$84M 1.54%
1,707,331
-1,512,028
-47% -$69.9M
KROS icon
22
Keros Therapeutics
KROS
$219M
$84M 1.54%
1,268,734
– –
NTRA icon
23
Natera
NTRA
$47B
$82.3M 1.51%
899,431
-55,050
-6% -$4.14M
TMO icon
24
Thermo Fisher Scientific
TMO
$230B
$76.7M 1.41%
132,000
-11,800
-8% -$6.62M
APLS
25
DELISTED
Apellis Pharmaceuticals
APLS
$76.3M 1.4%
1,297,800
+375,600
+41% +$23.9M
1
2 3 4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q1 2024 Portfolio in Review

As of Q1 2024, OrbiMed held 132 positions worth $5.46B, up 9% from $5.01B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

OrbiMed withdrew a net $312M in Q1 2024, closing 18 positions and reducing 29 holdings. Its most notable exit was RayzeBio, Inc. Common Stock, an estimated $147M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Miscellaneous and Industrials.

Against the trend, OrbiMed opened a new position in ArriVent BioPharma worth $54.1M.

  • OrbiMed's largest Q1 2024 buy was ArriVent BioPharma: 3,027,328 shares worth $54.1M.
  • OrbiMed added most to Merck in Q1 2024, an estimated $32.2M increase.
  • OrbiMed's biggest Q1 2024 reduction was SpringWorks Therapeutics, cutting an estimated $69.9M.
  • OrbiMed fully exited RayzeBio, Inc. Common Stock in Q1 2024, selling an estimated $147M.
  • OrbiMed's ten largest holdings make up 39% of its $5.46B portfolio in Q1 2024.
  • OrbiMed opened 22 new positions and closed 18 in Q1 2024.
  • OrbiMed's portfolio value rose 9% quarter-over-quarter to $5.46B.

Based on OrbiMed's 13F filing for Q1 2024, filed 15 May 2024.